Hyperlipidemia Market Size and Forecast 2024-2033| Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG

Statin is group of medicine used for treatment dyslipidemia

Overview and Scope

Hyperlipidemia is a medical condition characterized by abnormally high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It is a common metabolic disorder and a significant risk factor for cardiovascular diseases.

Sizing and Forecast

The hyperlipidemia market size has grown steadily in recent years. It will grow from $19.41 billion in 2023 to $20.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $23.25 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Segmentation & Regional Insights

The hyperlipidemia market covered in this report is segmented –

1) By Type: Familial; Acquired

2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment

3) By Route of Administration: Oral; Parenteral

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users

North America was the largest region in the hyperlipidemia market in 2023. The regions covered in hyperlipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

Major Driver Impacting Market Growth

Increasing incidences of chronic disorders such as heart disease are expected to propel the growth of the hyperlipidemia market going forward. Heart diseases refer to diseases that affect the heart and its functioning. Hyperlipidemia treatment helps people suffering from heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function and reducing the need for invasive interventions. For instance, in March 2022, according to a report published by The Office for National Statistics, a UK-based government department, the number of deaths due to heart attacks increased from 19,440 in 2020 to 20,061 in 2021. Therefore, increasing incidences of chronic disorders such as heart disease drive the growth of the hyperlipidemia market.

Key Industry Players

Major players in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

The hyperlipidemia market report table of contents includes:

1. Executive Summary

2. Hyperlipidemia Market Characteristics

3. Hyperlipidemia Market Trends And Strategies

4. Hyperlipidemia Market – Macro Economic Scenario

5. Global Hyperlipidemia Market Size and Growth

26. South America Hyperlipidemia Market

27. Brazil Hyperlipidemia Market

28. Middle East Hyperlipidemia Market

29. Africa Hyperlipidemia Market

30. Hyperlipidemia Market Competitive Landscape And Company Profiles

Top Major Players: